CD38 and Miyoshi myopathy: More importantly, the combination of bortezomib and TRAIL treatment significantly increased apoptosis and decrease the number of CD38+/CD138Bright MM cells (Fig 4B and 4C), implying that bortezomib treatment can further sensitize myeloma cells without 8p21 deletion to TRAIL-mediated killing.